drugset / Trial / NCT01962987

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

NCT01962987

Phase 3 Completed 476 enrolled Actavis Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis

Timeline

Start
2013-03
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 0.5 g Topical

Indications